<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3d6add4a-5d95-4e63-9761-7e97a92137ba"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use GLUCAGON FOR INJECTION safely and effectively.  See full prescribing information for GLUCAGON FOR INJECTION. <br/>GLUCAGON for injection, for subcutaneous, intramuscular or intravenous use<br/>Initial U.S. Approval: 1960
</title>
   <effectiveTime value="20250331"/>
   <setId root="c5c431b4-5618-4ff4-954e-4c0fbfed67b6"/>
   <versionNumber value="5"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="608775388" root="1.3.6.1.4.1.519.1"/>
            <name>Fresenius Kabi USA, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="023648251" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-582" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-583" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-582" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-583" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="964475045" root="1.3.6.1.4.1.519.1"/>
                        <name>Fresenius Kabi USA, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="63323-185" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="7b640b4d-7280-43eb-b903-04f81702ae69"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20190130"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="63323-582" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Glucagon
</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Glucagon</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="63323-582-82" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43197" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190909"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="63323-583" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Glucagon<suffix/>
                              </name>
                              <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Glucagon</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator value="1" unit="mg"/>
                                    <denominator value="1" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="1H87NVF4DB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>GLUCAGON HYDROCHLORIDE
</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="76LA80IG2G" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>GLUCAGON</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>LACTOSE MONOHYDRATE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROCHLORIC ACID</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM HYDROXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-583-13" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA201849" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20150508"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="1" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="63323-185" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>Sterile Water
</name>
                              <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>Water</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIB">
                                 <quantity>
                                    <numerator value="1" unit="mL"/>
                                    <denominator value="1" unit="mL"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>WATER
</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>WATER</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="mL"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="63323-185-82" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43203" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, GLASS"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="ANDA088400" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="19840116"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                              </substanceAdministration>
                           </consumedIn>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C28161" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAMUSCULAR"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA201849" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190909"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s0">
               <id root="3f5d0b35-231a-4aae-8a55-46472b21d8ed"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20190925"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="87.600%" align="left"/>
                           <col width="12.400%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top">Indications and Usage (<linkHtml href="#s1">1</linkHtml>)
</td>
                                 <td align="right" valign="top">09/2019
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Dosage and Administration (<linkHtml href="#s4">2</linkHtml>)
</td>
                                 <td align="right" valign="top">09/2019
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Contraindications (<linkHtml href="#s10">4</linkHtml>)
</td>
                                 <td align="right" valign="top">09/2019
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Warnings and Precautions (<linkHtml href="#s11">5</linkHtml>)
</td>
                                 <td align="right" valign="top">09/2019
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="146cdad7-2a03-4da8-b809-bcfe2c41c6ad"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <effectiveTime value="20190925"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Glucagon for Injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor indicated:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item> for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes (<linkHtml href="#s2">1.1</linkHtml>)
</item>
                           <item> as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients (<linkHtml href="#s3">1.2</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s2">
                     <id root="e4406c0b-c6c9-4b8f-b518-2ec0a8e9c8d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Severe Hypoglycemia
</title>
                     <text>
                        <paragraph>Glucagon for Injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s3">
                     <id root="8d0c88a3-18d7-46bb-83ca-95cd3d6f8e2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Diagnostic Aid
</title>
                     <text>
                        <paragraph>Glucagon for Injection is indicated as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s4">
               <id root="f66ee74a-a4b9-4fcb-962e-77e3a66300cc"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20190925"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Dosage in adults and pediatric patients using the glucagon emergency kit for low blood sugar to treat severe hypoglycemia (<linkHtml href="#s6">2.2</linkHtml>)</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Adults and Pediatric Patients Weighing More Than 25 kg or for Pediatric Patients with Unknown Weight 6 Years and Older:<list listType="unordered" styleCode="Disc">
                                 <item>
                                    <caption>-
</caption>The recommended dosage is 1 mg (1 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously.
</item>
                                 <item>
                                    <caption>-
</caption>If there has been no response after 15 minutes, an additional 1 mg dose (1 mL) of Glucagon for Injection may be administered using a new kit while waiting for emergency assistance.
</item>
                              </list>
                           </item>
                           <item>Pediatric Patients Weighing Less Than 25 kg or for Pediatric Patients with Unknown Weight Less Than 6 Years of Age:<list listType="unordered" styleCode="Disc">
                                 <item>
                                    <caption>-
</caption>The recommended dosage is 0.5 mg (0.5 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously.
</item>
                                 <item>
                                    <caption>-
</caption>If there has been no response after 15 minutes, an additional 0.5 mg dose (0.5 mL) of Glucagon for Injection may be administered using a new kit while waiting for emergency assistance.
</item>
                              </list>
                           </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Important Administration Instructions for Using the Glucagon Emergency Kit for Low Blood Sugar to Treat</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Severe Hypoglycemia (<linkHtml href="#s5">2.1</linkHtml>)</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Glucagon for Injection is for subcutaneous, intramuscular, or intravenous injection.  Administer intravenously ONLY under medical supervision.
</item>
                           <item>See the Full Prescribing Information for administration instructions
</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Dosage in Adults for Using Glucagon for Injection Diagnostic Kit and Glucagon for Injection Single-Dose Vial as a Diagnostic Aid (<linkHtml href="#s8">2.4</linkHtml>)</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 mg to 0.5 mg administered intravenously or 1 mg administered intramuscularly; the recommended dose to relax the colon is 0.5 mg to 0.75 mg administered intravenously or 1 mg to 2 mg administered intramuscularly.
</item>
                           <item>See the Full Prescribing Information for administration instructions (<linkHtml href="#s7">2.3</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s5">
                     <id root="bd9994f5-0375-417e-a6f9-d11097b19d9d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Important Administration Instructions for Using the Glucagon Emergency Kit for Low Blood Sugar to Treat Severe Hypoglycemia
</title>
                     <text>
                        <paragraph>Glucagon for Injection is for subcutaneous, intramuscular, or intravenous injection.  Administer intravenously ONLY under medical supervision.
</paragraph>
                        <paragraph>Instruct patients and their caregivers on the signs and symptoms of severe hypoglycemia. Because severe hypoglycemia requires the help of others to recover, instruct the patient to inform those around them about Glucagon for Injection and its Instructions for Use. Administer Glucagon for Injection as soon as possible when severe hypoglycemia is recognized.
</paragraph>
                        <paragraph>Instruct the patient or caregiver to read the Instructions for Use at the time they receive a prescription for Glucagon for Injection. Emphasize the following instructions to the patient or caregiver:
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Using the supplied prefilled syringe, carefully insert the needle through the rubber stopper of the vial containing Glucagon for Injection powder and inject all the liquid from the syringe into the vial.
</item>
                           <item>Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted solution should be clear and colorless. Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use.
</item>
                           <item>The reconstituted solution is 1 mg per mL glucagon.
</item>
                           <item>Immediately after reconstitution, inject the solution subcutaneously or intramuscularly in the upper arm, thigh, or buttocks. In addition, healthcare providers may administer intravenously.
</item>
                           <item>Call for emergency assistance immediately after administering the dose.
</item>
                           <item>When the patient has responded to the treatment and is able to swallow, give oral carbohydrates to restore the liver glycogen and prevent recurrence of hypoglycemia.
</item>
                           <item>Discard any unused portion.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s6">
                     <id root="53b3d4bd-e758-4197-83fe-13968f700a55"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Dosage in Adults and Pediatric Patients for Using the Glucagon Emergency Kit for Low Blood Sugar to Treat Severe Hypoglycemia
</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adults and Pediatric Patients Weighing More Than 25 kg or for Pediatric Patients with Unknown Weight 6 Years and Older</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage is 1 mg (1 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously.
</item>
                           <item>If there has been no response after 15 minutes, an additional 1 mg dose (1 mL) of Glucagon for Injection may be administered using a new kit while waiting for emergency assistance.
</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients Weighing Less Than 25 kg or for Pediatric Patients with Unknown Weight Less Than 6 Years of Age</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage is 0.5 mg (0.5 mL) injected subcutaneously or intramuscularly into the upper arm, thigh, or buttocks, or intravenously.
</item>
                           <item>If there has been no response after 15 minutes, an additional 0.5 mg dose (0.5 mL) of Glucagon for Injection may be administered using a new kit while waiting for emergency assistance.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s7">
                     <id root="d114aa7c-ad00-4499-b1a1-d1c98fc3cff7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Important Administration Instruction for Using Glucagon for Injection Diagnostic Kit and Glucagon for Injection Single-Dose Vial as a Diagnostic Aid
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Reconstitute Glucagon for Injection with 1 mL of Sterile Water for Injection.  Using a syringe, withdraw all of the Sterile Water for Injection (if supplied) or 1 mL Sterile Water for Injection and inject into the Glucagon for Injection vial.
</item>
                           <item>Shake the vial gently until the powder is completely dissolved and no particles remain in the fluid. The reconstituted fluid should be clear and colorless. Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use.
</item>
                           <item>The reconstituted solution is 1 mg per mL glucagon.
</item>
                           <item>Immediately after reconstitution, inject the solution intravenously or intramuscularly into upper arm, thigh, or buttocks.
</item>
                           <item>Discard any unused portion.
</item>
                           <item>After the end of the diagnostic procedure, give oral carbohydrates to patients who have been fasting, if this is compatible with the diagnostic procedure.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s8">
                     <id root="1a62a8d0-5ca0-43ae-9727-1816e98aa8d8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage in Adults for Using Glucagon for Injection Diagnostic Kit and Glucagon for Injection Single-Dose Vial as a Diagnostic Aid
</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended diagnostic dose for relaxation of the stomach, duodenal bulb, duodenum, and small bowel is 0.2 mg to 0.5 mg administered intravenously or 1 mg administered intramuscularly; the recommended dose to relax the colon is 0.5 mg to 0.75 mg administered intravenously or 1 mg to 2 mg administered intramuscularly <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s38">12.2</linkHtml>)]</content>.
</item>
                           <item>The onset of action after an injection will depend on the organ under examination and route of administration <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#s38">12.2</linkHtml>)]</content>.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="15e862a1-0551-4dd8-92b4-42a7a82f3fab"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3  DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>Glucagon for Injection is a white lyophilized powder supplied as follows:
</paragraph>
                  <paragraph>
                     <content styleCode="underline">Treatment of Severe Hypoglycemia</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>1 mg single-dose vial of Glucagon for Injection with a 1 mL single-dose syringe of Sterile Water for Injection, USP (Glucagon Emergency Kit for Low Blood Sugar)
</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Use as a Diagnostic Aid</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>1 mg single-dose vial of Glucagon for Injection
</item>
                     <item>1 mg single-dose vial of Glucagon for Injection with a 1 mL single-dose vial of Sterile Water for Injection, USP  (Diagnostic Kit)
</item>
                  </list>
               </text>
               <effectiveTime value="20190925"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>For Injection (<linkHtml href="#s9">3</linkHtml>):
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Treatment of Severe Hypoglycemia: 1 mg single-dose vial of Glucagon for Injection with a 1 mL single-dose syringe of Sterile Water for Injection, USP (Glucagon Emergency Kit for Low Blood Sugar)
</item>
                           <item>Use as a Diagnostic Aid: 1 mg single-dose vial of Glucagon for Injection
</item>
                           <item>Use as a Diagnostic Aid: 1 mg single-dose vial of Glucagon for Injection with a 1 mL single-dose vial of Sterile Water for Injection, USP  (Diagnostic Kit)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="dd441be3-649c-4a2f-891d-bee42ecaa239"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>Glucagon for Injection is contraindicated in patients with:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Pheochromocytoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s12">5.1</linkHtml>)]</content>
                     </item>
                     <item>Insulinoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s13">5.2</linkHtml>)]</content> because of the risk of hypoglycemia
</item>
                     <item>Known hypersensitivity to glucagon or any of the excipients in Glucagon for Injection. Allergic reactions have been reported with glucagon and include anaphylactic shock with breathing difficulties and hypotension <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.3</linkHtml>)]</content>
                     </item>
                     <item>Glucagonoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s19">5.8</linkHtml>)]</content> because of risk of hypoglycemia when used as a diagnostic aid
</item>
                  </list>
               </text>
               <effectiveTime value="20190925"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pheochromocytoma (<linkHtml href="#s10">4</linkHtml>)
</item>
                           <item>Insulinoma (<linkHtml href="#s10">4</linkHtml>)
</item>
                           <item>Known hypersensitivity to glucagon or to any of the excipients (<linkHtml href="#s10">4</linkHtml>)
</item>
                           <item>Glucagonoma when used as a diagnostic aid (<linkHtml href="#s10">4</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s11">
               <id root="fa91f1ad-b8c3-4585-9ed8-a6df599a07e5"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20190925"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Catecholamine Release in Patients with Pheochromocytoma</content>: Contraindicated in patients with pheochromocytoma because Glucagon for Injection may stimulate the release of catecholamines from the tumor. (<linkHtml href="#s10">4</linkHtml>, <linkHtml href="#s12">5.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hypoglycemia in Patients with Insulinoma:</content> In patients with insulinoma, administration may produce an initial increase in blood glucose; however, Glucagon for Injection may stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. If a patient develops symptoms of hypoglycemia after a dose of Glucagon for Injection, give glucose orally or intravenously. (<linkHtml href="#s10">4</linkHtml>, <linkHtml href="#s13">5.2</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hypersensitivity and Allergic Reactions:</content> Allergic reactions have been reported and include generalized rash, and in some cases anaphylactic shock with breathing difficulties, and hypotension. (<linkHtml href="#s10">4</linkHtml>, <linkHtml href="#s14">5.3</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Lack of Efficacy in Patients with Decreased Hepatic Glycogen:</content> Glucagon for Injection is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for Glucagon for Injection to be effective. Patients with these conditions should be treated with glucose. (<linkHtml href="#s15">5.4</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Necrolytic Migratory Erythema (NME):</content> a skin rash, has been reported postmarketing following continuous glucagon infusion and resolved with discontinuation of the glucagon. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks. (<linkHtml href="#s16">5.5</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hyperglycemia in Patients with Diabetes Mellitus when Used as a Diagnostic Aid:</content> Treatment with Glucagon for Injection in patients with diabetes mellitus may cause hyperglycemia. Monitor diabetic patients for changes in blood glucose levels during treatment and treat if indicated.(<linkHtml href="#s17">5.6</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Blood Pressure and Heart Rate Increase in Patients with Cardiac Disease when Used as a Diagnostic Aid:</content> Glucagon for Injection may increase myocardial oxygen demand, blood pressure, and pulse rate. Cardiac monitoring is recommended in patients with cardiac disease during use of Glucagon for Injection as a diagnostic aid, and an increase in blood pressure and pulse rate may require therapy. (<linkHtml href="#s18">5.7</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Hypoglycemia in Patients with Glucagonoma when Used as a Diagnostic Aid:</content> Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia. Test patients suspected of having glucagonoma for blood levels of glucagon prior to treatment, and monitor blood glucose levels during treatment. If a patient develops hypoglycemia, give glucose orally or intravenously. (<linkHtml href="#s19">5.8</linkHtml>)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s12">
                     <id root="b4649d7c-496a-42b0-9109-9afa02431f71"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Catecholamine Release in Patients with Pheochromocytoma
</title>
                     <text>
                        <paragraph>Glucagon for Injection is contraindicated in patients with pheochromocytoma because glucagon may stimulate the release of catecholamines from the tumor <content styleCode="italics">[see Contraindications (<linkHtml href="#s10">4</linkHtml>)].</content>  If the patient develops a dramatic increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s13">
                     <id root="89e85eef-0cae-4ada-b3ce-e6f9ba549286"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hypoglycemia in Patients with Insulinoma
</title>
                     <text>
                        <paragraph>In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, Glucagon for Injection administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. Glucagon for Injection is contraindicated in patients with insulinoma <content styleCode="italics">[see Contraindications (<linkHtml href="#s10">4</linkHtml>)].</content> If a patient develops symptoms of hypoglycemia after a dose of Glucagon for Injection, give glucose orally or intravenously.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="616be164-d69c-4cfd-87c6-17632ef9b81a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hypersensitivity and Allergic Reactions
</title>
                     <text>
                        <paragraph>Allergic reactions have been reported with glucagon, these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Glucagon for Injection is contraindicated in patients with a prior hypersensitivity reaction <content styleCode="italics">[see Contraindications (<linkHtml href="#s10">4</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="f0c8ae37-31cd-420b-b134-ed055c6423ff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Lack of Efficacy in Patients with Decreased Hepatic Glycogen
</title>
                     <text>
                        <paragraph>Glucagon for Injection is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for Glucagon for Injection administration to be effective. Patients with these conditions should be treated with glucose.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="9ef4c0d7-ad85-4268-b808-c0c0a14a2999"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Necrolytic Migratory Erythema
</title>
                     <text>
                        <paragraph>Necrolytic migratory erythema (NME), a skin rash commonly associated with glucagonomas (glucagonproducing tumors) and characterized by scaly, pruritic erythematous plaques, bullae, and erosions, has been reported postmarketing following continuous glucagon infusion. NME lesions may affect the face, groin, perineum and legs or be more widespread. In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. Should NME occur, consider whether the benefits of continuous glucagon infusion outweigh the risks.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="9e349819-7280-4e9e-9e9d-4b1ef54d9629"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Hyperglycemia in Patients with Diabetes Mellitus when Used as a Diagnostic Aid
</title>
                     <text>
                        <paragraph>Treatment with Glucagon for Injection in patients with diabetes mellitus may cause hyperglycemia. Monitor diabetic patients for changes in blood glucose levels during treatment and treat if indicated.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s18">
                     <id root="08adc228-6ff9-48e3-b250-5edf34589175"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Blood Pressure and Heart Rate Increase in Patients with Cardiac Disease when Used as a Diagnostic Aid
</title>
                     <text>
                        <paragraph>Glucagon for Injection may increase myocardial oxygen demand, blood pressure, and pulse rate which may be life-threatening in patients with cardiac disease. Cardiac monitoring is recommended in patients with cardiac disease during use of Glucagon for Injection as a diagnostic aid, and an increase in blood pressure and pulse rate may require therapy.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="9ad069bd-e6aa-4794-aa99-798b9f30d330"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Hypoglycemia in Patients with Glucagonoma
</title>
                     <text>
                        <paragraph>Glucagon administered to patients with glucagonoma may cause secondary hypoglycemia.  Glucagon for Injection is contraindicated in patients with glucagonoma when used as a diagnostic aid <content styleCode="italics">[see Contraindications (<linkHtml href="#s10">4</linkHtml>)].</content> Test patients suspected of having glucagonoma for blood levels of glucagon prior to treatment, and monitor for changes in blood glucose levels during treatment.  If a patient develops symptoms of hypoglycemia after a dose of Glucagon for Injection, give glucose orally or intravenously.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s20">
               <id root="c2fe5043-f403-46e3-8e6a-9b5c74a5a7b9"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following important adverse reactions are described below and elsewhere in the labeling:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity and Allergic Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.3</linkHtml>)]</content>
                     </item>
                     <item>Necrolytic Migratory Erythema <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s16">5.5</linkHtml>)]</content>
                     </item>
                     <item>Hyperglycemia in Patients with Diabetes Mellitus when Used as a Diagnostic Aid <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s17">5.6</linkHtml>)]</content>
                     </item>
                     <item>Blood Pressure and Heart Rate Increase in Patients with Cardiac Disease when Used as a Diagnostic Aid <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s18">5.7</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20190925"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions ( &gt;5% or greater incidence): Injection site swelling, injection site erythema, vomiting, nausea, decreased blood pressure, asthenia, headache, dizziness, pallor, diarrhea, and somnolence.
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s21">
                     <id root="bf34a7c0-6df9-4711-a3e5-88f2649c2f10"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Studies Experience
</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in clinical trials of another drug and may not reflect the rates observed in practice.
</paragraph>
                        <paragraph>In a randomized single-blind clinical study of Glucagon for Injection, 29 healthy subjects received a single dose of 1 mg Glucagon for Injection intramuscularly. <linkHtml href="#t1">Table 1</linkHtml> shows the most common adverse reactions that were not present at baseline and occurred in at least 5% of patients.
</paragraph>
                        <table ID="t1" width="100%">
                           <caption>Table 1: Adverse Reactions Occurring in
≥ 5% of Healthy Subjects Who Received Glucagon for Injection Intramuscularly
</caption>
                           <col width="32.150%" align="left"/>
                           <col width="67.850%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">Glucagon for Injection<br/>(N=29)<br/>% of Patients
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nausea
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">17
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Vomiting
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">7
</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In a randomized, single-blind clinical study of Glucagon for Injection, 31 healthy subjects received a single dose of 1 mg Glucagon for Injection subcutaneously.  <linkHtml href="#t2">Table 2</linkHtml> shows the most common adverse reactions that were not present at baseline and occurred in at least 5% of patients.  <content styleCode="italics">(<linkHtml href="#s5">2.1</linkHtml>)].</content>
                        </paragraph>
                        <table ID="t2" width="100%">
                           <caption>Table 2: Adverse Reactions Occurring
≥5% in Healthy Subjects Who Received Glucagon for Injection Subcutaneously
</caption>
                           <col width="52.750%" align="left"/>
                           <col width="47.250%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule"/>
                                 <td align="center" valign="top" styleCode="Toprule Botrule Rrule">Glucagon for Injection<br/>(N=31)<br/>% of Patients
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Injection site swelling
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">58
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Injection site erythema
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">55
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Vomiting
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">36
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Nausea
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">32
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Decreased blood pressure
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Asthenia
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">23
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Headache
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">13
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Dizziness
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Pallor
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">10
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diarrhea
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Somnolence
</td>
                                 <td align="center" valign="top" styleCode="Botrule Rrule">7
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20190925"/>
                     <component>
                        <section ID="s22">
                           <id root="41c1e8d1-d969-405e-95ef-6e3ab5117a28"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Other Adverse Reactions</content>
                              </paragraph>
                              <paragraph>Hypertension and tachycardia have occurred with glucagon treatment.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s23">
                     <id root="a0cafe5f-0d3f-4a5f-adee-2affcdcbaec9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience
</title>
                     <text>
                        <paragraph>Additional adverse reactions have been identified during post-approval use of glucagon. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>hypoglycemia and hypoglycemic coma.  Patients taking indomethacin may be more likely to experience hypoglycemia following glucagon administration <content styleCode="italics">[see Drug Interactions (<linkHtml href="#s24">7</linkHtml>)]</content>.
</item>
                           <item>Necrolytic migratory erythema (NME) cases have been reported postmarketing in patients receiving continuous infusion of glucagon.
</item>
                        </list>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s24">
               <id root="7c3fedb1-4968-4886-ace8-1abacfb5b62e"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS
</title>
               <effectiveTime value="20190925"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Beta-blockers</content>: Patients taking beta-blockers may have a transient increase in pulse and blood pressure. (<linkHtml href="#s25">7.1</linkHtml>)
</item>
                           <item>
                              <content styleCode="italics">Indomethacin:</content> In patients taking indomethacin Glucagon for Injection may lose its ability to raise glucose or may produce hypoglycemia. (7.2)
</item>
                           <item>
                              <content styleCode="italics">Anticholinergic drugs:</content> Concomitant use of anticholinergic drugs with Glucagon for Injection for use as a diagnostic aid is not recommended. (7.3)
</item>
                           <item>
                              <content styleCode="italics">Warfarin:</content> Glucagon for Injection may increase the anticoagulant effect of warfarin. (7.4)
</item>
                           <item>
                              <content styleCode="italics">Insulin:</content> Monitor blood glucose when Glucagon for Injection is used as a diagnostic aid in patients receiving insulin. (7.5)
</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s25">
                     <id root="ed97844d-0374-4f67-aee0-755545cd9774"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1
</title>
                     <text>
                        <table ID="t3" width="100%">
                           <caption>Table 3:  Clinically Significant Drug Interactions with Glucagon for Injection
</caption>
                           <col width="17.100%" align="left"/>
                           <col width="82.900%" align="left"/>
                           <tbody>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Beta-Blockers</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given Glucagon for Injection.
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">The increase in blood pressure and heart rate may require therapy in patients with coronary artery disease.
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Indomethacin</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">In patients taking indomethacin, Glucagon for Injection may lose its ability to raise blood glucose or may even produce hypoglycemia.
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Monitor blood glucose levels during glucagon treatment of patients taking indomethacin.
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Anticholinergic Drugs</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="middle" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">The concomitant use of anticholinergic drugs and Glucagon for Injection increases the risk of gastrointestinal adverse reactions due to additive effects on inhibition of gastrointestinal motility.
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Concomitant use of anticholinergic drugs with Glucagon for Injection for use as a diagnostic aid is not recommended.
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Warfarin</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Glucagon for Injection may increase the anticoagulant effect of warfarin.
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Monitor patients for unusual bruising or bleeding, as adjustments in warfarin dosage may be required.
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Insulin</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Clinical Impact:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Insulin acts antagonistically to glucagon.
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="italics">Intervention:</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">Monitor blood glucose when Glucagon for Injection is used as a diagnostic aid in patients receiving insulin.
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s26">
               <id root="c3b4ef7d-4e2f-4cdd-b71d-f205f44e613f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20190925"/>
               <component>
                  <section ID="s27">
                     <id root="376f4c01-c7bb-4289-b08d-8edb8320fb33"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20190925"/>
                     <component>
                        <section ID="s28">
                           <id root="8e822ec5-545d-4b16-84de-91fc9b3648c4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data from case reports and a small number of observational studies with glucagon use in pregnant women over decades of use have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Multiple small studies have demonstrated a lack of transfer of pancreatic glucagon across the human placental barrier during early gestation. In rat and rabbit reproduction studies, no embryofetal toxicity was observed with glucagon administered by injection during the period of organogenesis at doses representing up to 100 and 200 times the human dose, respectively, based on body surface area (mg/m<sup>2</sup>) <content styleCode="italics">(see <linkHtml href="#s29">Data</linkHtml>).</content>
                              </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2%-4% and 15%-20%, respectively.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s29">
                           <id root="2a85e0c5-497f-4c03-a3c2-e32f9a858330"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                           <component>
                              <section ID="s30">
                                 <id root="565de453-ac95-4f1d-a1fa-aa74453be3a6"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In rats and rabbits given glucagon by injection at doses of 0.4, 2.0, and 10 mg/kg (up to 100 and 200 times the human dose based on mg/m<sup>2</sup> for rats and rabbits, respectively) there was no evidence of increased malformations or embryofetal lethality.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190925"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s31">
                     <id root="7cda462d-39ed-4d7a-bc3b-7568ddbcbaf4"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20190925"/>
                     <component>
                        <section ID="s32">
                           <id root="429495c3-21e9-457b-9404-2f82b3017d8b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information available on the presence of glucagon in human or animal milk,  the effects of glucagon on the breastfed child or the effects of glucagon on milk production. However, glucagon is a peptide and would be expected to be broken down to its constituent amino acids in the infant's digestive tract and is therefore, unlikely to cause harm to an exposed infant.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s33">
                     <id root="156b34c7-a1dd-4bd1-8cf8-e4905d815fdd"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>The safety and effectiveness of Glucagon for Injection for the treatment of severe hypoglycemia in pediatric patients with diabetes have been established.
</paragraph>
                        <paragraph>Safety and effectiveness for use as a diagnostic aid during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in pediatric patients have not been established.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s34">
               <id root="aaf45efe-9d1b-4368-8b03-33a504ebaa19"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE
</title>
               <text>
                  <paragraph>If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, increase in blood pressure and pulse rate.  In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed.  If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.
</paragraph>
               </text>
               <effectiveTime value="20190925"/>
            </section>
         </component>
         <component>
            <section ID="s35">
               <id root="ec3531a7-7df4-458d-a2e3-49f76eb3b02a"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>Glucagon is an antihypoglycemic agent and a gastrointestinal motility inhibitor.  It is produced by solid phase peptide synthesis.  The chemical structure of the glucagon is identical to human glucagon. Glucagon is a single-chain polypeptide containing 29 amino acid residues. The structure of glucagon is:
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50.000%" align="left"/>
                     <col width="50.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td colspan="2" align="center" valign="top">
                              <renderMultiMedia ID="f01" referencedObject="mm01"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" valign="top">Molecular Formula = C<sub>153</sub>H<sub>225</sub>N<sub>43</sub>O<sub>49</sub>S               
</td>
                           <td align="left" valign="top">               Molecular Weight = 3483
</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Glucagon for Injection is a sterile, lyophilized white powder in a 3 mL vial for subcutaneous, intramuscular or intravenous use.  The reconstituted solution contains glucagon as hydrochloride 1 mg per mL and lactose monohydrate (107 mg).  Glucagon for Injection is supplied at pH 2.5 to 3.5 and is soluble in water.
</paragraph>
               </text>
               <effectiveTime value="20190925"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Figure
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s36">
               <id root="4b6dfab6-06b6-4ca3-9e76-5753dec4fb01"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12  CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20190925"/>
               <component>
                  <section ID="s37">
                     <id root="8030779a-bea1-4ebb-b2de-e230cfe922b4"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action
</title>
                     <text>
                        <paragraph>Glucagon increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver. Hepatic stores of glycogen are necessary for glucagon to produce an antihypoglycemic effect. Extrahepatic effects of glucagon include relaxation of the smooth muscle of the stomach, duodenum, small bowel, and colon.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s38">
                     <id root="1ae9c717-76d1-4e66-9617-0f20e7cb461f"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <effectiveTime value="20190925"/>
                     <component>
                        <section ID="s39">
                           <id root="b60ae62f-350e-41df-8764-39e9c470d085"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Treatment of Severe Hypoglycemia</content>
                              </paragraph>
                              <paragraph>Blood glucose concentration rises within 10 minutes of injection and maximal concentrations are attained at approximately 30 minutes after injection (see Figure 1). The duration of hyperglycemic action after intravenous or intramuscular injection is 60 to 90 minutes.
</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Figure 1. Recovery from Insulin Induced Hypoglycemia (mean blood glucose) After Intramuscular Injection of 1 mg of Another Glucagon for Injection Product in Type I Diabetic Men</content>
                              </paragraph>
                              <renderMultiMedia ID="f02" referencedObject="mm02"/>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                     <component>
                        <observationMedia ID="mm02">
                           <text>Figure
</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="glu02-0004-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <section ID="s40">
                           <id root="b70a0fe2-c71c-4287-99a9-ac4f19930882"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Diagnostic Aid</content>
                              </paragraph>
                              <table ID="t4" width="100%">
                                 <caption>Table 4: Pharmacodynamic Properties of Another Glucagon for Injection Product For Intravenous Route
</caption>
                                 <col width="24.755%" align="left"/>
                                 <col width="14.937%" align="left"/>
                                 <col width="21.636%" align="left"/>
                                 <col width="21.556%" align="left"/>
                                 <col width="17.117%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup>Dose is determined based on the length of the procedure.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Route of Administration</content>
                                       </td>
                                       <td align="center" valign="bottom" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Dose</content>
                                          <content styleCode="bold">
                                             <sup>a</sup>
                                          </content>
                                       </td>
                                       <td align="left" valign="bottom" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Time of Maximal</content>
                                          <br/>
                                          <content styleCode="bold">Glucose</content>
                                          <br/>
                                          <content styleCode="bold">Concentration</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Time of Onset of</content>
                                          <br/>
                                          <content styleCode="bold">Action for GI Smooth Muscle Relaxation</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Duration of</content>
                                          <br/>
                                          <content styleCode="bold">Smooth Muscle Relaxation</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Lrule Rrule">Intravenous
</td>
                                       <td align="left" valign="top" styleCode="Botrule Rrule">0.25 to 0.5 mg
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">5 to 20 minutes
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">45 seconds
</td>
                                       <td align="left" valign="top" styleCode="Botrule Rrule">9 to 17 minutes
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <table ID="t5" width="100%">
                                 <caption>Table 5 Pharmacodynamic Properties of Another Glucagon for Injection Product For Intramuscular Route
</caption>
                                 <col width="24.755%" align="left"/>
                                 <col width="14.937%" align="left"/>
                                 <col width="21.636%" align="left"/>
                                 <col width="21.556%" align="left"/>
                                 <col width="17.117%" align="left"/>
                                 <tfoot>
                                    <tr>
                                       <td colspan="5" align="left" valign="top">
                                          <paragraph styleCode="footnote">
                                             <sup>a</sup>Dose is determined based on the length of the procedure.
</paragraph>
                                       </td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr>
                                       <td align="left" valign="bottom" styleCode="Toprule Botrule Lrule Rrule">
                                          <content styleCode="bold">Route of Administration</content>
                                       </td>
                                       <td align="center" valign="bottom" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Dose</content>
                                          <content styleCode="bold">
                                             <sup>a</sup>
                                          </content>
                                       </td>
                                       <td align="left" valign="bottom" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Time of Maximal</content>
                                          <br/>
                                          <content styleCode="bold">Glucose</content>
                                          <br/>
                                          <content styleCode="bold">Concentration</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Time of Onset of</content>
                                          <br/>
                                          <content styleCode="bold">Action for GI Smooth Muscle Relaxation</content>
                                       </td>
                                       <td align="center" valign="top" styleCode="Toprule Botrule Rrule">
                                          <content styleCode="bold">Duration of</content>
                                          <br/>
                                          <content styleCode="bold">Smooth Muscle Relaxation</content>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td rowspan="2" align="center" valign="top" styleCode="Botrule Lrule Rrule">Intramuscular
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">1 mg
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">30 minutes
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">8 to 10 minutes
</td>
                                       <td align="left" valign="top" styleCode="Botrule Rrule">12 to 27 minutes
</td>
                                    </tr>
                                    <tr>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">2 mg
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">30 minutes
</td>
                                       <td align="center" valign="top" styleCode="Botrule Rrule">4 to 7 minutes
</td>
                                       <td align="left" valign="top" styleCode="Botrule Rrule">21 to 32 minutes
</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In a study in healthy subjects, a subcutaneous dose of 1 mg Glucagon for Injection resulted on average a peak blood glucose concentration of 79.3 mg/dL with a median time of 50 minutes after injection.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s41">
                     <id root="167e81b3-13f9-46b5-abb5-5d7e991d55b9"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3  Pharmacokinetics
</title>
                     <effectiveTime value="20190925"/>
                     <component>
                        <section ID="s42">
                           <id root="98ccaf77-9470-4139-a2d3-a973ca7f75f0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Following subcutaneous administration of Glucagon for Injection, the median time to reach the maximum baseline uncorrected plasma glucagon concentrations of 3533 pg/mL was approximately 10 to 13 minutes after dosing Following intramuscular administration of 1 mg dose, the maximum baseline uncorrected plasma glucagon concentrations of 3391 pg/mL were attained approximately 10 minutes after dosing.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s43">
                           <id root="885f48a4-b37e-4738-aac4-84a399f1c2da"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>The mean apparent half-life of glucagon was about 42 minutes after subcutaneous administration. The mean apparent half-life of glucagon was 26 minutes after intramuscular administration.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                           <component>
                              <section ID="s44">
                                 <id root="b9b3039b-3f3d-440e-99bd-3c4758537013"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Glucagon is degraded in the liver, kidney, and plasma.
</paragraph>
                                 </text>
                                 <effectiveTime value="20190925"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s45">
               <id root="8f8c0e97-682a-4e7d-b1a3-be6795dcf261"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY
</title>
               <effectiveTime value="20190925"/>
               <component>
                  <section ID="s46">
                     <id root="4a558e11-a909-4b89-ae70-3685c5756453"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility
</title>
                     <effectiveTime value="20190925"/>
                     <component>
                        <section ID="s47">
                           <id root="cbf05640-a433-4f69-abcb-4ed963fb76d2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Long term studies in animals to evaluate carcinogenic potential have not been performed.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s48">
                           <id root="aed92bf7-0557-42c9-9e2b-4f469420da8b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Synthetic glucagon was negative in the bacterial reverse mutation assay (Ames test).  The clastogenic potential of synthetic glucagon in the Chinese Hamster Ovary (CHO) assay was positive in the absence of metabolic activation.  Doses of 100 and 200 mg/kg of glucagon of both pancreatic and recombinant origins gave slightly higher incidences of micronucleus formation in male mice but there was no effect in females.  The weight of evidence indicates that synthetic and recombinant glucagon are not different and do not pose a genotoxic risk to humans.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s49">
                           <id root="d8142967-042c-474c-8c51-0eeb5079fd6c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Glucagon was not tested in animal fertility studies.  Studies in rats have shown that pancreatic glucagon does not cause impaired fertility.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s50">
               <id root="c7767b4c-19eb-4ca2-b184-86bb1a639fcd"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <effectiveTime value="20190925"/>
               <component>
                  <section ID="s51">
                     <id root="8480a501-4de9-49f7-bb3a-bbad383ed26c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1 How Supplied
</title>
                     <text>
                        <paragraph>Glucagon for Injection is supplied as a sterile, lyophilized white powder available as follows:
</paragraph>
                        <table width="100%">
                           <col width="24.000%" align="left"/>
                           <col width="14.675%" align="left"/>
                           <col width="13.325%" align="left"/>
                           <col width="48.000%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                                    <content styleCode="bold">Presentation</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">NDC</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Strength</content>
                                 </td>
                                 <td align="left" valign="top" styleCode="Toprule Botrule Rrule">
                                    <content styleCode="bold">Description</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Treatment of Severe Hypoglycemia</content>
                                 </td>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Glucagon Emergency Kit for Low Blood Sugar
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">63323-582-82
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">1 mg per vial
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">1 mL single-dose vial of Glucagon for Injection with 1 mL single-dose syringe of Sterile Water for<br/>Injection, USP for reconstitution
</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                                    <content styleCode="bold">Use as a Diagnostic Aid</content>
                                 </td>
                                 <td colspan="2" align="left" valign="top" styleCode="Botrule Rrule"/>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">10 Single-dose vials
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">63323-596-13
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">1 mg per vial
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">1 mL single-dose vial of Glucagon for Injection
</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top" styleCode="Botrule Lrule Rrule">Diagnostic Kit
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">63323-593-03
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">1 mg per vial
</td>
                                 <td align="left" valign="top" styleCode="Botrule Rrule">1 mL single-dose vial of Glucagon for Injection with<br/>1 mL single-dose vial of Sterile Water for Injection,<br/>USP for reconstitution
</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s52">
                     <id root="4a8a0922-eaba-4141-8c7d-fd4e6580e543"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2 Recommended Storage
</title>
                     <effectiveTime value="20190925"/>
                     <component>
                        <section ID="s53">
                           <id root="e1356848-de42-4c42-81b8-0895cfd822d0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Before Reconstitution</content>
                              </paragraph>
                              <paragraph>The package containing Glucagon for Injection vials may be stored up to 24 months at 20° to 25° C (68° to 77° F) [see USP Controlled Room Temperature] prior to reconstitution.  Do not freeze.  Keep in the original package to protect from light.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s54">
                           <id root="92dba3c9-e08a-43ba-82e4-712e7c78f9d3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">After Reconstitution</content>
                              </paragraph>
                              <paragraph>Use reconstituted glucagon solution immediately.  Discard any unused portion <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#s7">2.3</linkHtml>)]</content>.
</paragraph>
                           </text>
                           <effectiveTime value="20190925"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s55">
               <id root="a5f596dd-fd67-4031-8ad5-8ac1a47ef0bd"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17  PATIENT COUNSELING INFORMATION
</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#s59">Patient Information</linkHtml> and <linkHtml href="#s60">Instructions for Use</linkHtml>).
</paragraph>
               </text>
               <effectiveTime value="20190925"/>
               <component>
                  <section ID="s56">
                     <id root="bab188e6-d5b3-463c-9e73-df1b2694aea3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Recognition of Severe Hypoglycemia</content>
                        </paragraph>
                        <paragraph>Inform patient and family members or caregivers on how to recognize the signs and symptoms of severe hypoglycemia and the risks of prolonged hypoglycemia.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s57">
                     <id root="e5853899-46ed-4a54-966c-3a5eb80027f9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <paragraph>Review the <linkHtml href="#s59">Patient Information</linkHtml> and <linkHtml href="#s60">Instructions for Use</linkHtml> with the patient and family members or caregivers.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
               <component>
                  <section ID="s58">
                     <id root="fccae0de-9c5f-4bb2-957a-1cefa4a78ba4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serious Hypersensitivity</content>
                        </paragraph>
                        <paragraph>Inform patients that allergic reactions can occur with Glucagon for Injection. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#s14">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20190925"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s59">
               <id root="e8c5e5d4-a692-4528-b6b0-8674eea11ae5"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="35.712%" align="left"/>
                     <col width="32.578%" align="left"/>
                     <col width="31.711%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="2" align="left" valign="top" styleCode="Botrule">
                              <paragraph styleCode="footnote">This Patient Information has been approved by the U.S. Food and Drug Administration
</paragraph>
                           </td>
                           <td colspan="2" align="right" valign="top" styleCode="Botrule">
                              <paragraph styleCode="footnote">Approved:  09/2019
</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td colspan="3" align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>
                              <content styleCode="bold">Glucagon (GLOO-ka-gon)</content>
                              <br/>
                              <content styleCode="bold">for injection, for subcutaneous, intramuscular or</content>
                              <br/>
                              <content styleCode="bold">intravenous use</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What is Glucagon?</content>
                              <br/>Glucagon is a prescription medicine used:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>to treat very low blood sugar (severe hypoglycemia) in people with diabetes.
</item>
                                 <item>to stop stomach movement (gastrointestinal motility inhibitor) in patients receiving radiology exams.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Who should not use Glucagon?</content>
                              <br/>Do not use Glucagon if:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>you have a tumor in the gland on top of your kidneys (adrenal gland) called a pheochromocytoma.
</item>
                                 <item>you have a tumor in your pancreas called an insulinoma.
</item>
                                 <item>you are allergic to glucagon or lactose or any of the ingredients in Glucagon. See the end of this Patient Information leaflet for a complete list of ingredients in Glucagon.
</item>
                                 <item>you have tumors in your pancreas called Glucagonomas because it could cause low blood sugar when used for your radiology exam.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I tell my doctor before using Glucagon?</content>
                              <br/>
                              <content styleCode="bold">Before using Glucagon, tell your doctor about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have kidney problems.
</item>
                                 <item>have pancreas problems.
</item>
                                 <item>have not had food or water for a long time (prolonged fasting or starvation).
</item>
                                 <item>have low blood sugar that does not go away (chronic hypoglycemia).
</item>
                                 <item>have heart problems.
</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if Glucagon will harm your unborn baby.
</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if Glucagon passes into your breast milk.<br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Tell your doctor about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins and herbal supplements. Glucagon may affect the way other medicines work, and other medicines may affect how Glucagon works. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">How should I use Glucagon?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Read the detailed <content styleCode="bold">
                                       <linkHtml href="#s60">Instructions for Use</linkHtml>
                                    </content> that come with Glucagon.
</item>
                                 <item>Use Glucagon exactly as your doctor tells you to.
</item>
                                 <item>Make sure that you and your family know how to use Glucagon the right way before you need it.
</item>
                                 <item>Act quickly. Having very low blood sugar for a period of time may be harmful.
</item>
                                 <item>
                                    <content styleCode="bold">Call for emergency medical help right after you use Glucagon.</content>
                                 </item>
                                 <item>If the person does not respond after 15 minutes, another dose may be given, if available.
</item>
                                 <item>Eat sugar or a sugar sweetened product such as a regular soft drink or fruit juice as soon as you are able to swallow.
</item>
                                 <item>Tell your doctor each time you use Glucagon. Your doctor may need to change the dose of your diabetes medicines.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of Glucagon?</content>
                              <br/>
                              <content styleCode="bold">Glucagon may cause serious side effects, including:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">High blood pressure</content>. Glucagon can cause high blood pressure in certain people with tumors in their adrenal glands.
</item>
                                 <item>
                                    <content styleCode="bold">Low blood sugar</content>. Glucagon can cause low blood sugar in patients with tumors in their pancreas called insulinomas and Glucagonomas by making too much insulin in their bodies.
</item>
                                 <item>
                                    <content styleCode="bold">Serious allergic reactions.</content> Call your doctor or get medical help <content styleCode="bold">right away</content> if you have a serious allergic reaction including:<list listType="unordered" styleCode="Circle">
                                       <item>rash
</item>
                                       <item>difficulty breathing
</item>
                                       <item>low blood pressure
</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">High blood sugar.</content> If you receive Glucagon before your radiology exam it can cause high blood sugar. Your doctor will monitor your blood sugar levels during your treatment.
</item>
                                 <item>
                                    <content styleCode="bold">Heart problems.</content> If you have heart problems and receive Glucagon before your radiology exam, you may have an increase in your blood pressure and pulse while using Glucagon which could be life threatening.Your doctor will monitor your heart during treatment.<br/>
                                    <br/>
                                 </item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">The most common side effects of Glucagon include:
</td>
                        </tr>
                        <tr>
                           <td align="left" valign="top" styleCode="Lrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>swelling at the injection site
</item>
                                 <item>redness at the injection site
</item>
                                 <item>vomiting
</item>
                                 <item>nausea
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>decreased blood pressure
</item>
                                 <item>weakness
</item>
                                 <item>headache
</item>
                                 <item>dizziness
</item>
                              </list>
                           </td>
                           <td align="left" valign="top" styleCode="Rrule">
                              <list listType="unordered" styleCode="Disc">
                                 <item>pale skin
</item>
                                 <item>diarrhea
</item>
                                 <item>sleepiness or drowsiness
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of Glucagon. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store Glucagon?</content>
                              <br/>
                              <content styleCode="bold">Before you mix the Glucagon powder and liquid:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store Glucagon at room temperature between 68°F to 77°F (20°C to 25°C) for up to 24 months (2 years).
</item>
                                 <item>Do not freeze Glucagon.
</item>
                                 <item>Keep Glucagon in its original package Glucagon and out of light.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Lrule Rrule">
                              <content styleCode="bold">After you mix the Glucagon powder and liquid:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Use Glucagon right away.
</item>
                                 <item>Throw away any unused Glucagon.
</item>
                                 <item>Glucagon should be clear and colorless. Do not use Glucagon if it is cloudy or if you see particles in the solution.
</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">Keep Glucagon and all medicines out of the reach of children</content>.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of Glucagon:</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use Glucagon for a condition for which it was not prescribed. Do not give Glucagon to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about Glucagon that is written for health professionals.
</td>
                        </tr>
                        <tr>
                           <td colspan="3" align="left" valign="top" styleCode="Botrule Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in the Glucagon?</content>
                              <br/>
                              <content styleCode="bold">Active Ingredient:</content> Glucagon<br/>
                              <content styleCode="bold">Inactive ingredients:</content> lactose monohydrate and sterile water for reconstitution<br/>For more information, go to www.fresenius-kabi.com/us or call 1-800-551-7176.
</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20190925"/>
            </section>
         </component>
         <component>
            <section ID="s60">
               <id root="60f4d737-3915-4845-91cf-738c0f462dd8"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Instructions for Use</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Glucagon (GLOO-ka-gon)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">for injection, for subcutaneous, intramuscular or intravenous use</content>
                  </paragraph>
                  <paragraph>Read this Instructions for Use before you start using Glucagon and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment. Talk to your doctor or pharmacist if you have any questions about how to use Glucagon.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">Read and become familiar with this Instructions for Use before an emergency happens</content>.
</item>
                     <item>Show your family members and others where you keep your Glucagon Emergency Kit for Low Blood Sugar and how to use it the right way.
</item>
                     <item>Call for emergency medical help right after you use Glucagon.
</item>
                     <item>Do not share your Glucagon syringes or needles with another person. You may give other people a serious infection or other people may get a serious infection from you.
</item>
                     <item>The prefilled syringe that comes with your Glucagon Emergency Kit for Low Blood Sugar is meant for use with Glucagon only. Do not use Glucagon syringes to inject other medicines.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How should I store Glucagon?</content>
                  </paragraph>
                  <paragraph>Before you mix the Glucagon powder and liquid:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store Glucagon at room temperature between 68° to 77°F (20° to 25°C). Check the expiration date on your vial of Glucagon. Do not use Glucagon if the expiration date has passed.
</item>
                     <item>Do not freeze Glucagon.
</item>
                     <item>Keep Glucagon in its original package and Glucagon out of light.
</item>
                  </list>
                  <paragraph>After you mix the Glucagon powder and liquid:
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Use Glucagon right away.
</item>
                     <item>Throw away any unused Glucagon.
</item>
                     <item>Glucagon should be clear and colorless. Do not use Glucagon if it is cloudy or if you see particles in the solution.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Supplies you will need for your Glucagon injection (See <linkHtml href="#f03">Figure A</linkHtml>):</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>1 Glucagon Emergency Kit for Low Blood Sugar that contains:<list listType="unordered" styleCode="Circle">
                           <item>1 vial that contains 1 mg of Glucagon for injection and 1 prefilled glass syringe with attached needle that contains 1 mL of Sterile Water for Injection.
</item>
                        </list>
                     </item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="100.000%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <renderMultiMedia ID="f03" referencedObject="mm03"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="top">Figure A
</td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="Disc">
                     <item>1 puncture resistant container for throwing away used needles and syringes. See “How should I dispose of (throw away) used Glucagon prefilled syringes” at the end of these instructions.
</item>
                     <item>Cotton ball or gauze pad (not included in kit)
</item>
                     <item>
                        <content styleCode="bold">Preparing the Glucagon dose:</content>
                     </item>
                     <item>The Glucagon medicine comes as a dry powder. Before you use Glucagon, you must mix the dry powder with the syringe of sterile water that comes in the Glucagon Emergency Kit for Low Blood Sugar. <content styleCode="bold">Do not use any other liquid to mix the medicine.</content>
                     </item>
                     <item>Check that the orange plastic cap on your vial of Glucagon is firmly attached. <content styleCode="bold">Do not</content>  use the vial of Glucagon if the orange plastic cap is loose or missing.
</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50.000%" align="left"/>
                     <col width="12.667%" align="left"/>
                     <col width="37.333%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 1</content>. Using your thumb, flip the orange plastic cap off the Glucagon vial (<content styleCode="bold">See <linkHtml href="#f04">Figure B</linkHtml>
                              </content>).
</td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure B</content>
                              <br/>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f04" referencedObject="mm04"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 2</content>. Pick up the prefilled syringe containing sterile water. Hold the syringe with 1 hand and with your other hand pull the needle cover off the syringe (<content styleCode="bold">See <linkHtml href="#f05">Figure C</linkHtml>
                              </content>).<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not</content> remove the plastic backstop from the syringe.
</item>
                              </list>
                           </td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure C</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f05" referencedObject="mm05"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 3.</content> Pick up the Glucagon vial. Hold the vial of dry powder with 1 hand and with your other hand push the needle of the prefilled syringe through the center of the rubber stopper (<content styleCode="bold">See <linkHtml href="#f06">Figure D</linkHtml>
                              </content>).
</td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure D</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f06" referencedObject="mm06"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 4</content>. Hold the vial and syringe together, with the needle still inserted into the vial. Carefully turn the vial and syringe together right side up. Slowly push the plunger down until the syringe is empty (<content styleCode="bold">See <linkHtml href="#f07">Figure E</linkHtml>
                              </content>).<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not take the syringe out of the vial.</content>
                                 </item>
                              </list>
                           </td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure E</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f07" referencedObject="mm07"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 5</content>. Hold the entire unit (the vial and syringe) in 1 hand and gently shake the vial until the powder is completely dissolved (<content styleCode="bold">See <linkHtml href="#f08">Figure F</linkHtml>
                              </content>).<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Do not use if it is cloudy or if you see particles in the solution.
</item>
                                 <item>
                                    <content styleCode="bold">Do not take the syringe out of the vial.</content>
                                 </item>
                              </list>
                           </td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure F</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f08" referencedObject="mm08"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 6</content>. Firmly hold the vial and syringe together, with the needle still inserted into the vial. Carefully turn the vial and syringe together upside down. Gently pull down on the plunger and slowly withdraw all of the liquid into the syringe (<content styleCode="bold">See <linkHtml href="#f09">Figure G</linkHtml>
                              </content>).<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Do not pull the plunger out of the syringe.
</item>
                              </list>
                           </td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure G</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f09" referencedObject="mm09"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 7.</content> Keep the needle inside the vial. Check the syringe for air bubbles. If you see bubbles, tap the syringe until the bubbles rise to the top of the syringe (<content styleCode="bold">See <linkHtml href="#f10">Figure H</linkHtml>
                              </content>). Gently push on the plunger to move only the air bubbles back into the vial.
</td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure H</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f10" referencedObject="mm10"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 8</content>. Hold the vial and syringe as shown (<content styleCode="bold">See <linkHtml href="#f11">Figure I</linkHtml>
                              </content>)
</td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure I</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f11" referencedObject="mm11"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Giving the Glucagon for Injection:</content>
                           </td>
                           <td align="left" valign="top"/>
                           <td align="left" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 9.</content> Choose the injection site (<content styleCode="bold">See <linkHtml href="#f12">Figure J</linkHtml>
                              </content>).<br/>Common injection sites for Glucagon are upper arms, thighs, or buttocks. Patient does not need to be laying down to administer the medication as long as the common injection sites can be easily accessed.
</td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure J</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f12" referencedObject="mm12"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 10</content>. With 1 hand gently pinch the skin at the injection site. With your other hand insert the needle into the skin and push the syringe plunger down until the syringe is empty (<content styleCode="bold">See <linkHtml href="#f13">Figure K</linkHtml>
                              </content>).
</td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure K</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f13" referencedObject="mm13"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">After Giving the Glucagon injection:</content>
                           </td>
                           <td align="left" valign="top"/>
                           <td align="center" valign="top"/>
                        </tr>
                        <tr>
                           <td align="left" valign="top">
                              <content styleCode="bold">Step 11</content>. Pull the needle out of the skin and press on the injection site (<content styleCode="bold">See <linkHtml href="#f14">Figure L</linkHtml>
                              </content>). Use a gauze pad or cotton ball (not included<br/>in the kit) if needed to press the injection site to make sure there is no direct contact with the skin.
</td>
                           <td align="right" valign="top">
                              <content styleCode="bold">Figure L</content>
                           </td>
                           <td align="center" valign="top">
                              <renderMultiMedia ID="f14" referencedObject="mm14"/>
                              <br/>
                              <br/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Throw away your used syringe with the needle attached and any Glucagon you did not use. See “<content styleCode="bold">
                        <linkHtml href="#p01">How should I dispose of (throw away) used Glucagon prefilled syringes</linkHtml>
                     </content>” at the end of these instructions.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 12. Turn the person on their side.</content> When an unconscious person awakens, they may vomit. Turning the person on their side will lessen the chance of choking.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 13. Call for emergency medical help right away. If the person does not respond after 15 minutes,</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">another dose may be given, if available.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 14. Feed the person as soon as they are awake and able to swallow</content>.
</paragraph>
                  <paragraph>Give the person a fast acting source of sugar (such as a regular soft drink or fruit juice) and a long acting source of sugar (such as crackers and cheese or a meat sandwich).
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Step 15. Even if the Glucagon for Injection treatment wakes the person, tell their doctor right away.</content> The doctor should be told whenever a severe drop in blood sugar (hypoglycemia reaction) happens. The person's dose of diabetes medicine may need to be changed.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Hypoglycemia may happen again after receiving Glucagon for Injection treatment.  Early symptoms of hypoglycemia may include:</content>
                  </paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="52.400%" align="left"/>
                     <col width="47.600%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>sweating
</item>
                                 <item>drowsiness
</item>
                                 <item>dizziness
</item>
                                 <item>sleep disturbances
</item>
                                 <item>irregular heartbeat (palpitation)
</item>
                                 <item>anxiety
</item>
                                 <item>tremor
</item>
                                 <item>blurred vision
</item>
                                 <item>hunger
</item>
                                 <item>slurred speech
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>restlessness
</item>
                                 <item>depressed mood
</item>
                                 <item>tingling in the hands, feet, lips, or tongue
</item>
                                 <item>irritability
</item>
                                 <item>abnormal behavior
</item>
                                 <item>lightheadedness
</item>
                                 <item>unsteady movement
</item>
                                 <item>inability to concentrate
</item>
                                 <item>personality changes
</item>
                                 <item>headache
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>If not treated early, hypoglycemia may worsen and the person may have severe hypoglycemia. Signs of severe hypoglycemia include:
</paragraph>
                  <table width="100%" styleCode="Noautorules">
                     <col width="50.300%" align="left"/>
                     <col width="49.700%" align="left"/>
                     <tbody>
                        <tr>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>confusion
</item>
                                 <item>unconsciousness
</item>
                              </list>
                           </td>
                           <td align="left" valign="top">
                              <list listType="unordered" styleCode="Disc">
                                 <item>seizures
</item>
                                 <item>death
</item>
                              </list>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph ID="p01">
                     <content styleCode="bold">How should I dispose of (throw away) Glucagon pre-filled syringes?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Put used syringes in a FDA-cleared sharps disposal container right away after use. <content styleCode="bold">Do not throw away (dispose of) loose needles and syringes in your household trash.</content>
                     </item>
                     <item>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:<list listType="unordered" styleCode="Disc">
                           <item>made of a heavy-duty plastic,
</item>
                           <item>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
</item>
                           <item>upright and stable during use,
</item>
                           <item>leak-resistant, and
</item>
                           <item>properly labeled to warn of hazardous waste inside the container.
</item>
                        </list>
                     </item>
                     <item>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.
</item>
                     <item>Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Keep Glucagon and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. Approved: 09/2019
</paragraph>
                  <paragraph>The brand names mentioned in this document are the trademarks of their respective owners.
</paragraph>
                  <paragraph>Manufactured by:  <br/>Fresenius Kabi<br/>Lake Zurich, IL 60047
</paragraph>
                  <paragraph>
                     <renderMultiMedia ID="f15" referencedObject="mm15"/>
                  </paragraph>
                  <paragraph>www.fresenius-kabi.com/us<br/>451541
</paragraph>
               </text>
               <effectiveTime value="20190925"/>
               <component>
                  <observationMedia ID="mm03">
                     <text>Figure A
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm04">
                     <text>Figure B
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm05">
                     <text>Figure C
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm06">
                     <text>Figure D
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm07">
                     <text>Figure E
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm08">
                     <text>Figure F
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm09">
                     <text>Figure G
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm10">
                     <text>Figure H
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm11">
                     <text>Figure I
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm12">
                     <text>Figure J
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm13">
                     <text>Figure K
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm14">
                     <text>Figure L
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="mm15">
                     <text>Fresenius Kabi Logo
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s61">
               <id root="edf1d814-2d0e-4589-a848-c09f23e9c54c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Glucagon 1 mg Vial Label<br/>
                     </content>509813<br/>
                     <content styleCode="bold">Glucagon</content> for Injection (Synthetic)<br/>
                     <content styleCode="bold">1 mg per vial<br/>
                     </content>For subcutaneous, intramuscular or intravenous injection.<br/> Reconstitute with Sterile Water for Injection, USP<br/> Rx only
</paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia ID="f17" referencedObject="MM17"/>
                  <br/>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Sterile Water 1 mL Single-Dose Syringe Label<br/>
                     </content>
                     <content styleCode="bold">1 mL Single-Dose Syringe<br/> Sterile Water for Injection, USP</content>
                     <br/>For drug diluent use only<br/>
                     <content styleCode="bold">1 mL
</content>
                  </paragraph>
                  <br/>
                  <br/>
                  <renderMultiMedia ID="f18" referencedObject="MM18"/>
                  <br/>
                  <br/>
                  <br/>
                  <paragraph>
                     <content styleCode="bold">PACKAGE LABEL - PRINCIPAL DISPLAY - Glucagon 1 mg Top of Clamshell<br/>
                     </content>NDC 63323-582-82<br/>Reconstitute with accompanying diluent immediately before use.
</paragraph>
                  <paragraph>
                     <content styleCode="bold">Glucagon Emergency Kit for Low Blood Sugar<br/> Glucagon for Injection 1 mg per vial<br/> This Kit contains: </content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>One single-dose vial with 1 mg of Glucagon for Injection 
</item>
                     <item>One prefilled syringe with 1 mL of Sterile Water for Injection, USP (Diluent)
</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">For subcutaneous, intramuscular or intravenous injection</content>
                  </paragraph>
                  <paragraph>Rx only<br/>
                     <br/>
                     <renderMultiMedia ID="f19" referencedObject="MM19"/>
                  </paragraph>
               </text>
               <effectiveTime value="20190130"/>
               <component>
                  <observationMedia ID="MM17">
                     <text>vial
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM18">
                     <text>water
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM19">
                     <text>clamshell
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="glu02-0004-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>